Project Grant R01AI201785
Award Date 8/20/26
Completion Date 7/31/31
Dollars Obligated $856K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
- Federal Grant Award Summary The University of Notre Dame DU Lac received a $459,439 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 7, 2025, with completion scheduled for June 30, 2027. The grant supports research addressing acute cellular rejection (ACR) in organ transplantation through investigation of CD8+ T cell alloreactivity and its relationship to viral...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame Du Lac $197,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how tyloxapol inhibits mycobacterial type VII secretory activity. The research addresses the molecular mechanisms by which tyloxapol, a non-ionic detergent, impairs the ESX-1 secretion system essential for mycobacterial infection. Preliminary data demonstrate that sub-critical...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $709,532 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct systematic research into the cytoplasmic pathway for peptidoglycan recycling in Pseudomonas aeruginosa, an antibiotic-resistant gram-negative bacterial pathogen responsible for recurrent lung infections in cystic fibrosis patients. The work addresses two specific aims. The first...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $158,000 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct spatial mapping research on Pseudomonas aeruginosa biofilm organization and stress resilience. The research combines multiple spatial analytical techniques—fluorescence microscopy, polarized light microscopy, and confocal Raman microscopy—to map the localization of alkyl quinolones...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $750,787 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate central memory stem-cell-like follicular helper T cells (CTFH) and their contribution to durable donor-specific anti-HLA antibodies (DSA) and chronic antibody-mediated rejection (ABMR) in kidney transplant recipients. The research addresses mechanisms of chronic rejection in solid organ...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $251,324 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered organ transplants resistant to antibody-mediated rejection through synthetic biology platforms. The research focuses on designing signal-inducible, drug-controllable endopeptidases for localized antibody degradation within transplanted tissue. The award funds...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Notre Dame $237,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop monoclonal antibody-conjugated nanoparticles for targeted cytomegalovirus antiviral delivery. The project addresses limitations of current CMV therapies—ganciclovir and valganciclovir—which...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame $614,655 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bladder inflammatory and immune responses to fungal catheter-associated urinary tract infections caused by Candida albicans. The research addresses a significant knowledge gap in understanding fungal catheter-associated urinary tract infections, which now represent the second leading...